Dr. Walid Abi-Saab
worries, Good morning, Thank No hope you can Onno. good afternoon, well. everybody. me you. hear I
it's kinase of the my So excerpts walk TYKX the pleasure inhibitors. through some data and to you our salt-inducible on
time Just a to put and of going to concentrate presentation it the I studies and of will because take the on specific it I'm I doing include refer will you because not context, be some so forth which elements back dropout RPRs of X full to on studies. information a rates -- today. lot these each otherwise on in the on safety so in of
So have please. the can next if you slide,
the on quite excited TYKX, about So this we're class.
of TYKX As IL-XX. a the it signals TYKX p-STAT through right IL-XX of you can number affects now. hot very the pathway mediators imagine, field inflammation in and it's also and interferon, like
number a or TYKX as potential inflammatory blocking indications a has As other autoimmune lupus of such in of TYKX interferonopathies. psoriasis, result, types and several inhibiting as bowel disease, such
based safety target that also a about excited we're quite it profile. target, -- promising So also appears is has this on fact that the this
to you Our own the program. inhibitor as which, I advanced XXXX we've selective is end know, Phase the of proprietary TYKX a
next If you can go to the slide.
to at look ratio, compared we X changes also where is dose look you consistent across a of signal in see at a is placebo. X-week the own signal in with XXXX areas the above doses that so clearly endpoints, X:X:X not We We we the we when curve forth, from board. so this weeks near as is in The and But additional trial near based that and as the randomize on on data placebo. high-dose to evidenced study. in and report we be score. we PASI indication, generally see from safe this found well well What the as What results response by trial. patients out X It's XX the patients a saw competitors know was randomized our on or a shape data XXXX XX at detection positive clearly trial nowhere and on body had experiencing X well the of the XX tolerated. we -- plateau PASI efficacy or that, surface of nowhere only on as X our Here plateau. high in we as
early Now well this in say, we doses. completed year, mentioned planned wanted based in range or on as of the right in should safety will the this full that ulcerative finding earlier, last dose to previously studies based in margin that a psoriasis had higher on in the I tox longer study as that an as enable as -- range explore And XXXX. year a early Onno upcoming we XXXX, in II sometime ongoing increase study were And Phase matter colitis, is now. us study evaluate in to fact, dose term
On of to disposition what baseline achieved they on the the slide, based the essentially PASI I'm show the and subjects trying here next change of on score.
at this is So week X.
X and it. on of subjects achieved at see You Y who the the axis can the PASI axis proportion score the
subjects, where response. And patients. the is on the dark high we have we the dose XX of where can having you had each represents So XXXX one XX dose low imagine a patient green uptick
has that see we speak. greater PASI so achieve So than X% a so patient And very each -- to increment one is clearly about can clearly XX. you
one dose, have XX. We that people barely see XX, the one if PASI of high We that cutoff cutoff and you do below on a at see And of had on placebo active, X then achieving that another are goal. the XX. them you
the cytokines promising some same with at we a that such as kinases, these profile both particular our that's mediators reduction as IL-XX. approach about a inhibitors. very slide, very TNF-alpha, regulatory We're both of So that increase inhibition were with that And And pro-inflammatory of development also can time They potential mediators excited efficacy, novel potentially -- role through in could signaled actually kinases in a in can an will and was increasing pioneering the a mechanism Clearly, but the of by such of cartoon also overall, elucidating as do further with ulcerative critical a inflammation. immunosuppression some excited. in treatment that colitis, the And and other we very role played role this these with inflammation of in picture a here. in we're on consequence has salt-inducible reducing I have inflammation. different indications. indication, inflammatory mediators. is depicted talk salt-inducible pleased why evaluating is but a reason as other well XXXX detected. quite psoriasis, results. the action was supports of kinase X we're as In this potentially next the pathways, we in areas well. overall the bit is these affect This in as pro-inflammatory that the Salt-inducible our the Galapagos long-term both but kinase regulatory chronic what signal observed of affect
with X, for broad across have level level we a for multiple selectivity potential of board and have X We believe different type X/X well of the we of a as type together compounds and here. as that potency, applications the number
next tolerated, inhibitor studies in X experience our which the summarizing we safe XXXX slide, week well generally molecule we Overall, the a as X be the bit that for and our signal which in to with well detection were On SIKX/X took I'm forward that general. in XXXX, bodes duration. found is platform a
the able that you perfectly candidate. important it not inform we future high. were margin data guide development some toxicity, We Now explore ideal Nonetheless, been of the was knew that some XXXX us to clinic and we've platform, for clear, investing was dose-limiting we that this felt as by in not heavily us the was know, generating the that to which, virtue whole in. of start help to very will that be
in we while case was we TURTLE worthwhile details, at efficacy where study with In needed which So the in signs achieve were fact, a evidence I'll it CALOSOMA I'll the about endpoints, indication ulcerative talk patients signal across trial. of objective you we specifically animal We endoscopy evidence of Mayo are of activity placebo. not XX duration, very do exciting more and -- and X And based that's of was the histology, seen in study, achieving looked knew as subsequent colitis, when secondary in today. the clinic the talk models. look SEA this we when of higher very observed the actually in These activity that pre-clinically that look show by not arthritis, endpoints, which clearly saw see any in in further the at translated us have we've out study, anymore of of versus observations subsequent when I case developing solidly on clinical PASI did week it the not to X on score, seen In and us. XX much psoriasis the number you on in slides, we clearly that the none rheumatoid later the what the at and for molecule. And biologic definitely RA. actually, in for will we any exposures efficacy see we toughest about examined
remind a week of On the -- drug so on trial for the the between we and XXXX at drug I end see due and similar had you XX on proportion placebo. dropouts you we randomization placebo. active next In reasons X:X:X at had the showing did In of the couple up the subjects a XX slide, graph other XX I I'm or where end We case, of as placebo, this and on and the placebo. between drug with end, XX COVID to on X.
you this trial. placebo. you And will can patient X% clearly from about imagine in So be on XXXX active how XX% one separates to placebo compared on see can
between you the On that were biologic change This see duration, from had study, we slide, XX had way, and UC the When response actually a and we is such, the had in placebo look on X. this not patient on for randomization, primary naive. baseline, naive Jack where trial. this short the ulcerative population, X-week X:X:X large people that you at the the for XX in about relatively remind that relatively on that at Mayo change a tells large are is time. we coverage score would but we to endpoint all just colitis, which, And this any they by trial, next versus which the active you, the as tox the was placebo is
you this -- we objective slide, the when endoscopic graph, which the at endoscopic we Mayo, to at if at the look next on of the X on looked you be when the score healing. response, to definition used X we subscore specifically a improvement, is go However, look the side of when or of days left-hand when the called endpoints, in old mucosal
the out X underwent of who see XX% out patients trial which that close You end versus X those the on of or to have is XX, X about we of of active. endoscopy at XX%
Again that the scores which And did we these can who drug be of So those think have, who I'm should the taken the context and patients at drug. endoscopic it improvement -- But detection those for clearly this is here have the of robots -- the graph numbers that right-hand look looked we to largest the signal had on very side -- And each a small the we histology then tried in their on score, the to not studies, you score. clear majority, endpoint. nonetheless, signal. showing see follow fact are the are signal. see histology on into the primary we are
-- a marker bottom, fecal of those is colitis. X an for who X market the ones at their As the patients, histology normalized the have virtually matter inflammation are the the calprotectin, who are lowest for fact, actually score who which on ulcerative or
naive well a data are in this from these whole. encouraged the the So platform in a look think signs despite ulcerative the placebo when all I response that this positive at with large as for had all, we we population. we fact But bodes the biologic colitis,
will that summarize signs that clear us these salt-inducible something doesn't last activity you an further that with with that you excited with in able now to allow kinase activity that we us the are pharmacologic with back signal given that that of pleased So potential volunteer and that XXXX. was the with portfolio data conclude you the evaluate not engagement. psoriasis, important of is SIKX/X turn fully We've it to inflammatory colitis. we to and profile the compounds that goal indications, hope with I is molecules a point mechanism is I then clearly activity. clinic discovery salt-inducible It's to studies. translate and I would the of inhibitor potent we've margin seen clinic SIKX/X to late-stage indication. better Filius. there have one in development to that novel therefore, in the And slide, biologic we bring XXXX we've I'm inhibitors a when up come clinic -- as which of also our seen, want important We action, like to know over you. biologic in support of go our inflammatory quite in ulcerative seen more we in Thank agree there kinase work Bart the efficacy that our evidence inhibition in healthy will very are in of in on and And work very to the data these think my that, to higher we with detection we've that that and target that have our with short and clinical necessary to I'll seen in be studies
